|92.51||+0.6200||+0.67%||Vol 8.43M||1Y Perf 19.01%|
|Jun 29th, 2022 16:03 DELAYED|
|-0.51 -0.55%||- -|
|Target Price||92.53||Analyst Rating||Moderate Buy 2.00|
|Potential %||0.02||Finscreener Ranking||★★★ 49.98|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★+ 53.97|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★+ 55.38|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||★★+ 42.97|
|Price Range Ratio 52W %||87.07||Earnings Rating||Sell|
|Market Cap||233.94B||Earnings Date||28th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||28th Jul 2022|
|Estimated EPS Next Report||1.68|
|EPS Growth Next 5 Years %||10.10|
|Avg. Weekly Volume||12.61M|
|Avg. Monthly Volume||12.13M|
|Avg. Quarterly Volume||11.76M|
Merck & Company Inc. (NYSE: MRK) stock closed at 92.51 per share at the end of the most recent trading day (a 0.67% change compared to the prior day closing price) with a volume of 8.43M shares and market capitalization of 233.94B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. CEO is Robert M. Davis.
The one-year performance of Merck & Company Inc. stock is 19.01%, while year-to-date (YTD) performance is 20.71%. MRK stock has a five-year performance of 44.34%. Its 52-week range is between 70.89 and 95.72, which gives MRK stock a 52-week price range ratio of 87.07%
Merck & Company Inc. currently has a PE ratio of 16.70, a price-to-book (PB) ratio of 5.76, a price-to-sale (PS) ratio of 4.42, a price to cashflow ratio of 13.80, a PEG ratio of 2.32, a ROA of 14.74%, a ROC of 22.77% and a ROE of 42.76%. The company’s profit margin is 25.87%, its EBITDA margin is 37.10%, and its revenue ttm is $53.98 Billion , which makes it $21.35 revenue per share.
Of the last four earnings reports from Merck & Company Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.68 for the next earnings report. Merck & Company Inc.’s next earnings report date is 28th Jul 2022.
The consensus rating of Wall Street analysts for Merck & Company Inc. is Moderate Buy (2), with a target price of $92.53, which is +0.02% compared to the current price. The earnings rating for Merck & Company Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Merck & Company Inc. has a dividend yield of 2.92% with a dividend per share of $2.76 and a payout ratio of 104.00%.
Merck & Company Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.97, ATR14 : 2.09, CCI20 : 89.24, Chaikin Money Flow : 0.03, MACD : 0.74, Money Flow Index : 58.93, ROC : 6.11, RSI : 59.22, STOCH (14,3) : 74.66, STOCH RSI : 0.54, UO : 59.00, Williams %R : -25.34), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Merck & Company Inc. in the last 12-months were: Arpa Garay (Option Excercise at a value of $223 559), Caroline Litchfield (Option Excercise at a value of $144 559), Caroline Litchfield (Sold 18 335 shares of value $1 668 503 ), David Michael Williams (Option Excercise at a value of $180 590), Dean Y. Li (Option Excercise at a value of $161 854), Frank Clyburn (Option Excercise at a value of $207 622), Frank Clyburn (Sold 39 762 shares of value $3 493 879 ), Jannie Oosthuizen (Option Excercise at a value of $223 559), Julie L. Gerberding (Option Excercise at a value of $0), Julie L. Gerberding (Sold 192 540 shares of value $16 925 364 ), Kenneth C. Frazier (Option Excercise at a value of $0), Kenneth C. Frazier (Sold 663 881 shares of value $54 611 361 ), Lisa LeCointe-Cephas (Option Excercise at a value of $167 192), Michael A Klobuchar (Option Excercise at a value of $221 642), Richard R. DeLuca (Option Excercise at a value of $0), Richard R. DeLuca (Sold 165 187 shares of value $14 548 563 ), Rita A. Karachun (Option Excercise at a value of $244 023), Rita A. Karachun (Sold 25 000 shares of value $2 211 215 ), Sanat Chattopadhyay (Option Excercise at a value of $0), Sanat Chattopadhyay (Sold 24 619 shares of value $2 149 731 ), Steven C. Mizell (Option Excercise at a value of $415 156)
Fri, 24 Jun 2022 16:24 GMT Merck Now What- TipRanks. All rights reserved.
Fri, 29 Apr 2022 12:46 GMT Merck & Company (MRK) Receives a Buy from Wells Fargo- TipRanks. All rights reserved.
Wed, 27 Apr 2022 08:46 GMT Merck Reports Earnings Tomorrow What Can We Expect- TipRanks. All rights reserved.
Tue, 26 Apr 2022 19:29 GMT Merck: A Dividend Growth Stock Worth Considering- TipRanks. All rights reserved.
Wed, 13 Apr 2022 14:14 GMT Merck Stock: COVID-19 Drug Should Boost 2022 Numbers- TipRanks. All rights reserved.
Wed, 16 Mar 2022 01:57 GMT Merck & Company (MRK) Gets a Hold Rating from Berenberg Bank- TipRanks. All rights reserved.
Wed, 02 Mar 2022 16:44 GMT Merck: A Reliable Stock for Income Investors- TipRanks. All rights reserved.
Mon, 07 Feb 2022 17:21 GMT Merck & Company (MRK) Received its Third Buy in a Row- TipRanks. All rights reserved.
Thu, 03 Feb 2022 13:15 GMT Merck & Company (MRK) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Thu, 20 Jan 2022 14:25 GMT Merck & Company (MRK) Gets a Buy Rating from Mizuho Securities- TipRanks. All rights reserved.
Sun, 02 Jan 2022 12:27 GMT Is Merck & Co. a Value Stock- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.